Department of Orthopaedic Surgery, Emory University School of Medicine, Atlanta, Georgia.
Department of Orthopaedic Surgery, Tulane University School of Medicine, New Orleans, Louisiana.
J Arthroplasty. 2023 Mar;38(3):548-554. doi: 10.1016/j.arth.2022.09.018. Epub 2022 Sep 18.
It is unclear if hepatitis C virus (HCV) negatively impacts outcomes of revision total hip arthroplasty (rTHA). The purpose of this study is to trend recent rTHA utilization in patients who have HCV and compare postoperative complication rates versus a matched cohort.
All patients who underwent rTHA were retrospectively identified in a national database. Patients who had HCV (n = 1,746) were matched 1:3 with a matching group (n = 5,238) for age, gender, and several comorbidities. Cochran-Armitage tests were used to analyze trends in the annual proportion of rTHA performed in patients who had HCV from 2010 to 2019. Rates of 90-day medical and prosthesis-related complications within 2 years postoperatively were compared with multivariable logistic regressions.
The annual proportion of rTHA performed in patients who had HCV significantly increased from 2010 to 2019 (P < .001). Patients who had HCV exhibited significantly higher rates of acute kidney injuries (7.6% versus 4.4%; odds ratio [OR] 1.50), transfusions (20.6% versus 14.6%; OR 1.38), and re-revisions for prosthetic joint infection (10.9% versus 6.5%; OR 1.73). In subgroup analyses, rates of re-revision for prosthetic joint infection after initial aseptic rTHA (7.1% versus 3.8%; OR 1.82) and periprosthetic fracture after initial septic rTHA (4.5% versus 1.6%; OR 2.77) were significantly higher in the HCV cohort.
Similar to primary THA, patients who have HCV exhibit significantly increased complication rates after rTHA. With growing utilization in recent years, these data suggest that this population will comprise an increasingly larger proportion of rTHA procedures performed in the coming years.
目前尚不清楚丙型肝炎病毒(HCV)是否会对翻修全髋关节置换术(rTHA)的结果产生负面影响。本研究的目的是分析近年来 HCV 患者 rTHA 利用趋势,并与匹配队列比较术后并发症发生率。
在国家数据库中回顾性识别所有接受 rTHA 的患者。将 HCV 患者(n=1746)按年龄、性别和几种合并症与匹配组(n=5238)1:3 匹配。采用 Cochran-Armitage 检验分析 2010 年至 2019 年 HCV 患者 rTHA 年度比例的变化趋势。采用多变量逻辑回归比较术后 2 年内 90 天内的医疗和假体相关并发症发生率。
2010 年至 2019 年, HCV 患者 rTHA 的年度比例显著增加(P<0.001)。HCV 患者急性肾损伤(7.6% vs. 4.4%;比值比 [OR] 1.50)、输血(20.6% vs. 14.6%;OR 1.38)和假体关节感染的再翻修(10.9% vs. 6.5%;OR 1.73)发生率显著较高。亚组分析显示,初始无菌 rTHA 后假体关节感染的再翻修率(7.1% vs. 3.8%;OR 1.82)和初始感染性 rTHA 后假体周围骨折率(4.5% vs. 1.6%;OR 2.77)在 HCV 组中显著较高。
与初次 THA 相似,HCV 患者 rTHA 后并发症发生率显著增加。近年来 rTHA 应用日益增多,这些数据表明,未来几年,该人群将占 rTHA 手术的比例越来越大。